X
[{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Unveils New Strategic Plan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for OTL-101
Filters
Companies By Therapeutic Area
Details:
The investigational gene therapy products, including OTL-101 resulted in overall survival of 100% through the end of follow-up. At one year, event-free survival was 97% in U.S. study patients and 100% in UK study patients.
Lead Product(s):
OTL-101
Therapeutic Area: Genetic Disease
Product Name: OTL-101
Highest Development Status: Phase II/ Phase III
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 11, 2021
Details:
Orchard Therapeutics to establish OTL-200, OTL-103, OTL-203 and OTL-201 programs as top near-term priorities and reduce investment in OTL-101and OTL-300.
Lead Product(s):
OTL-101
Therapeutic Area: Genetic Disease
Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 07, 2020